{
      "Rank": 1,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "PROCHYMAL\u00ae",
            "Placebo"
      ],
      "ArmGroupInterventionName": [
            "Drug: PROCHYMAL\u00ae",
            "Drug: Placebo"
      ],
      "ArmGroupLabel": [
            "Prochymal",
            "Placebo"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT00690066"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purpose of this study is to establish the safety and efficacy of multiple administrations of PROCHYMAL\u00ae in participants recently diagnosed with type 1 diabetes mellitus."
      ],
      "BriefTitle": [
            "PROCHYMAL\u00ae (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "OTHER"
      ],
      "CollaboratorName": [
            "Juvenile Diabetes Research Foundation"
      ],
      "CompletionDate": [
            "December 19, 2011"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Type 1 Diabetes Mellitus",
            "Type 1 Diabetes",
            "Diabetes Mellitus, Insulin-Dependent",
            "Juvenile Diabetes"
      ],
      "ConditionAncestorId": [
            "D000044882",
            "D000008659",
            "D000004700",
            "D000001327",
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Glucose Metabolism Disorders",
            "Metabolic Diseases",
            "Endocrine System Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC18",
            "BC19",
            "All",
            "BC20"
      ],
      "ConditionBrowseBranchName": [
            "Nutritional and Metabolic Diseases",
            "Gland and Hormone Related Diseases",
            "All Conditions",
            "Immune System Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Diabetes Mellitus",
            "Type 1 Diabetes"
      ],
      "ConditionBrowseLeafId": [
            "M6267",
            "M6269",
            "M10791",
            "M24556",
            "M7014",
            "M3781",
            "M9352"
      ],
      "ConditionBrowseLeafName": [
            "Diabetes Mellitus",
            "Diabetes Mellitus, Type 1",
            "Metabolic Diseases",
            "Glucose Metabolism Disorders",
            "Endocrine System Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000003920",
            "D000003922"
      ],
      "ConditionMeshTerm": [
            "Diabetes Mellitus",
            "Diabetes Mellitus, Type 1"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "Diabetes mellitus refers to disorders in which the body has trouble controlling its blood glucose levels. There are two main types of diabetes: type 1 and type 2. Type 1 diabetes mellitus (T1DM), which is being studied in this trial, is an autoimmune disorder in which the body's own immune system attacks and destroys the cells that make insulin. These cells are called beta cells. As beta cells are destroyed, less insulin can be made. This causes blood sugar levels to increase above normal and can cause life-threatening hypo- and hyper-glycemic reactions. For this reason, people with type 1 diabetes must take insulin to help control their blood sugar levels. Over time, poorly controlled diabetes can lead to a variety of serious health conditions, including heart disease, stroke, blindness, amputations, kidney disease, and nerve damage. Insulin is the primary method of controlling diabetes by regulating blood glucose levels, but it may not reverse or prevent disease progression. The active ingredient in PROCHYMAL\u00ae is adult human mesenchymal stem cells (MSCs). MSCs have been shown to interact with the immune cells in the body, reducing inflammation and assisting in tissue repair. This study will help determine whether MSCs can protect normal pancreatic tissue from autoimmune attack and repair damaged pancreatic tissue, leading to an increase in insulin production and decrease in circulating blood glucose. The characteristics and biologic activity of PROCHYMAL\u00ae, along with a good safety profile in human trials to date, suggest that PROCHYMAL\u00ae may be a good candidate for addressing Type 1 Diabetes."
      ],
      "DispFirstPostDate": [
            "December 23, 2021"
      ],
      "DispFirstPostDateType": [
            "Actual"
      ],
      "DispFirstSubmitDate": [
            "December 20, 2021"
      ],
      "DispFirstSubmitQCDate": [
            "December 20, 2021"
      ],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nParticipant must have a diagnosis of type 1 diabetes mellitus based on the American Diabetes Association (ADA) criteria.\nParticipant must be screened between 2 and 20 weeks from initial T1DM diagnosis\nParticipants must be between the ages of 12 and 35 (inclusive).\nParticipant must have at least one diabetes-related autoantibody present (either GAD or IA-2).\nParticipant must have some beta cell function as determined by C-peptide testing (at least 0.2 pmol/mL (0.6 ng/mL) during MMTT.\nParticipants must be willing to comply with \"intensive diabetes management\" as directed by the Investigator with the goal of maintaining blood glucose as close to normal as possible (i.e., glycosylated hemoglobin A1c (HbA1c) value of \u2264 7.0%).\nParticipants must be willing to comply with the schedule of study visits and protocol requirements.\n\nExclusion Criteria:\n\nParticipant has Body Mass Index (BMI) \u2265 30.\nParticipant has evidence of retinopathy at baseline.\nParticipant has abnormally high lipid levels.\nParticipant has abnormal blood pressure.\nParticipant has an abnormal serum creatinine.\nParticipant has evidence of clinically significant proteinuria.\nParticipant has diabetic ketoacidosis.\nParticipant is being treated for a severe active infection of any type.\nA female participant who is breast-feeding, pregnant, or intends to become pregnant during the study.\nParticipant with clinically relevant uncontrolled medical condition not associated with diabetes (e.g. hematologic, renal, hepatic, neurologic, cardiac, or respiratory).\nParticipant has received an investigational drug (not approved by the FDA) for any indication 30 days prior to the screening visit.\nParticipant is allergic to bovine or porcine products.\nParticipant has evidence of active malignancy or prior history of active malignancy that has not been in remission for at least 5 years.\nParticipant has any medical condition, which in the opinion of the Investigator, rendered his/her participation in this study unsuitable."
      ],
      "EnrollmentCount": [
            "63"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000893",
            "D000000998",
            "D000000890"
      ],
      "InterventionAncestorTerm": [
            "Anti-Inflammatory Agents",
            "Antiviral Agents",
            "Anti-Infective Agents"
      ],
      "InterventionArmGroupLabel": [
            "Prochymal",
            "Placebo"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Hypo",
            "All",
            "Infe",
            "Infl"
      ],
      "InterventionBrowseBranchName": [
            "Hypoglycemic Agents",
            "All Drugs and Chemicals",
            "Anti-Infective Agents",
            "Anti-Inflammatory Agents"
      ],
      "InterventionBrowseLeafAsFound": [
            "Unsuccessful"
      ],
      "InterventionBrowseLeafId": [
            "M9517",
            "M172956",
            "M186752",
            "M3369",
            "M3466",
            "M3366"
      ],
      "InterventionBrowseLeafName": [
            "Insulin",
            "Insulin, Globin Zinc",
            "Remestemcel-l",
            "Anti-Inflammatory Agents",
            "Antiviral Agents",
            "Anti-Infective Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low",
            "high",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells",
            "Intravenous infusion of excipients of PROCHYMAL\u00ae"
      ],
      "InterventionMeshId": [
            "C000711674"
      ],
      "InterventionMeshTerm": [
            "Remestemcel-l"
      ],
      "InterventionName": [
            "PROCHYMAL\u00ae",
            "Placebo"
      ],
      "InterventionOtherName": [
            "ex vivo cultured adult human mesenchymal stem cells",
            "Prochymal"
      ],
      "InterventionType": [
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "T1DM",
            "Type 1 Diabetes Mellitus",
            "Type 1 Diabetes",
            "Diabetes Mellitus, Insulin-Dependent",
            "Juvenile Diabetes",
            "Adult Human Stem Cells",
            "Mesenchymal Stem Cells",
            "MSCs",
            "Insulin",
            "Osiris",
            "Prochymal"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "December 23, 2021"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "December 20, 2021"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Mesoblast, Inc."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Birmingham",
            "La Jolla",
            "Stanford",
            "Gainesville",
            "Miami",
            "Lexington",
            "Minneapolis",
            "Henderson",
            "Las Vegas",
            "Chapel Hill",
            "Charlotte",
            "Cincinnati",
            "Dayton",
            "Carlisle",
            "Bartlett",
            "Dallas",
            "Salt Lake City",
            "Norfolk",
            "Madison",
            "Milwaukee"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States"
      ],
      "LocationFacility": [
            "University of Alabama, Division of Endocrinology & Metabolism",
            "Scripps Whittier Diabetes Institute",
            "Stanford University",
            "University of Florida",
            "Diabetes Research Institute",
            "University of Kentucky",
            "University of Minnesota",
            "Desert Endocrinology CRC",
            "Nevada Alliance Against Diabetes",
            "University of North Carolina Diabetes Care Center",
            "American Health Research, Inc.",
            "The Lindner Clinical Trial Center",
            "Providence Health Partners - Center for Clinical Research",
            "Cumberland Valley Endocrinology",
            "AM Diabetes & Endocrinology Center",
            "The University of Texas Southwestern Medical Center",
            "Optimum Clinical Research, Inc.",
            "The Strelitz Diabetes Center, Eastern VA Medical School",
            "University of Wisconsin Health- West Clinic",
            "Clinical and Transitional Science Institute"
      ],
      "LocationState": [
            "Alabama",
            "California",
            "California",
            "Florida",
            "Florida",
            "Kentucky",
            "Minnesota",
            "Nevada",
            "Nevada",
            "North Carolina",
            "North Carolina",
            "Ohio",
            "Ohio",
            "Pennsylvania",
            "Tennessee",
            "Texas",
            "Utah",
            "Virginia",
            "Wisconsin",
            "Wisconsin"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "35294",
            "92037",
            "94305",
            "32610",
            "33136",
            "40502",
            "55455",
            "89052",
            "89101",
            "27599",
            "28207",
            "45219",
            "45439",
            "17015",
            "38133",
            "75390",
            "84102",
            "23510",
            "53717",
            "53226"
      ],
      "MaximumAge": [
            "35 Years"
      ],
      "MinimumAge": [
            "12 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL\u00ae (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Mesoblast, Ltd."
      ],
      "OrgStudyId": [
            "901"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Mesoblast, Inc."
      ],
      "OverallOfficialName": [
            "Mahboob Rahman, MD"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 12, 2010"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "C-peptide area under the concentration curve (AUC) response (MMTT)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "1 year"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [
            "Peak C-peptide response (MMTT)",
            "Basal C-peptide response",
            "Total daily insulin dose (units/kg)",
            "Glycosylated hemoglobin (HbA1c) levels",
            "Number of severe and documented hypoglycemic events",
            "Changes in levels of glutamic acid decarboxylase (GAD) or islet antigen 2 (IA-2) autoantibodies"
      ],
      "SecondaryOutcomeTimeFrame": [
            "2 years",
            "2 years",
            "2 years",
            "2 years",
            "2 years",
            "2 years"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "June 11, 2008"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "December 2021"
      ],
      "StdAge": [
            "Child",
            "Adult"
      ],
      "StudyFirstPostDate": [
            "June 4, 2008"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "June 2, 2008"
      ],
      "StudyFirstSubmitQCDate": [
            "June 2, 2008"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": []
}